Trial review
Tirzepatide and Cardiovascular Outcomes
SURPASS-CVOT randomised 13,299 participants to tirzepatide or dulaglutide over about 4.5 years and found tirzepatide non-inferior for major adverse cardiovascular events. Non-inferiority to another GLP-1 is a different claim from cardiovascular benefit versus placebo, and the two are frequently conflated.
The design decision that shapes everything
SURPASS-CVOT used an active comparator — dulaglutide, an established GLP-1 receptor agonist with its own cardiovascular outcome data — rather than placebo. With 13,299 participants over roughly 4.5 years, it is by far the largest and longest trial in the tirzepatide programme.
The result was non-inferiority for major adverse cardiovascular events. Tirzepatide was not worse than dulaglutide.
Why non-inferiority is not superiority
A non-inferiority result establishes that a new treatment does not fall below an accepted comparator by more than a prespecified margin. It does not establish that the new treatment is better, and it does not by itself establish benefit against no treatment.
The inference many readers draw — "tirzepatide reduces cardiovascular risk" — requires an additional step: that dulaglutide's own placebo-controlled benefit transfers. That is a reasonable clinical inference and it is not what this trial measured.
This distinction matters commercially because cardiovascular benefit is a powerful marketing claim, and it is being made on the back of a non-inferiority result.
What the trial does contribute
Long-duration safety data in a very large population, which the shorter weight-management trials cannot provide. For a medication likely to be taken indefinitely, 4.5 years of cardiovascular safety data in 13,299 people is substantively reassuring in a way that a 72-week weight trial is not.
Status of our record
We have captured the design, population, comparator, duration and headline finding. The full publication details, absolute event rates and secondary endpoints remain to be captured and are marked pending rather than summarised from secondary sources.
ClinicalTrials.gov NCT04255433. Funded by Eli Lilly.
| Design | Phase 3 cardiovascular outcomes trial |
|---|---|
| Population | not captured |
| Sample size | 13,299 randomised |
| Intervention | not captured |
| Comparator | Dulaglutide |
| Duration | Approximately 4.5 years |
| Primary endpoint | Major adverse cardiovascular events |
| Main result | Non-inferior to dulaglutide for MACE. This is not a demonstration of superiority over placebo |
Show this figure as a table
| Step | Stage | What happens |
|---|---|---|
| 1 | Who was eligible | Not captured — inclusion and exclusion criteria pending. |
| 2 | What they received | Not captured — intervention and dose pending. |
| 3 | What it was compared against | Dulaglutide |
| 4 | For how long | Approximately 4.5 years |
| 5 | What was measured first | Major adverse cardiovascular events |
| 6 | What the group average was | Non-inferior to dulaglutide for MACE. This is not a demonstration of superiority over placebo |
| 7 | What it does not tell you | A group average is not a prediction for any individual reader. |
| Question | Position |
|---|---|
| Average effect in the studied population | Reported above Verified |
| Your individual outcome | Not predicted by any trial |
| Effect of a compounded preparation | Not studied — this was an approved product |
| Effect at doses outside the protocol | Not studied |
| Effect after stopping | Only SURMOUNT-4 tested withdrawal |
| Long-term safety beyond the window | Outside the observation period |
Questions readers actually ask
Does tirzepatide reduce cardiovascular risk?
SURPASS-CVOT found it non-inferior to dulaglutide, another GLP-1. That is not the same as demonstrating superiority, or benefit against placebo.
Why use an active comparator?
Once effective treatments exist, placebo-controlled cardiovascular trials raise ethical questions. Active comparators are standard, and they change what the result can claim.
Related on this site
- Research hubResearch
- SURMOUNT-1 Tirzepatide Trial ExplainedResearch
- SURMOUNT-3 Tirzepatide Trial ExplainedResearch
- SURMOUNT-4: Weight Maintenance and Tirzepatide WithdrawalResearch
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Tirzepatide and Fatty Liver / MASHResearch
- Tirzepatide and Diabetes Prevention Over 176 WeeksJournal
- Tirzepatide and Chronic Kidney DiseaseResearch
GLP-1 Tirzepatide Review. “Tirzepatide and Cardiovascular Outcomes.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/research/tirzepatide-cardiovascular-outcomes/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.